Complementary treatments of chronic viral hepatitis C;Traitements complémentaires de l'hépatite chronique virale C

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 2, 2006, Pages 197-214

  Thevenot, Thierry ^a   Di Martino, Vincent ^a   Lunel Fabiani, Françoise ^b   Vanlemmens, Claire ^a   Becker, Marie Claude ^a   Bronowicki, Jean Pierre ^c   Bresson Hadni, Solange ^a   Miguet, Jean Philippe ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; ALPHA TOCOPHEROL; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMFEBUTAMONE; AMISULPRIDE; ANTIDEPRESSANT AGENT; CITALOPRAM; ERYTHROPOIETIN; FLUOXETINE; FLUPENTIXOL; GLUTATHIONE; GRANULOCYTE COLONY STIMULATING FACTOR; NEFAZODONE; NORTRIPTYLINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAROXETINE; PEGINTERFERON; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 11; RIBAVIRIN; SERTRALINE; URSODEOXYCHOLIC ACID;

ANEMIA; CLINICAL TRIAL; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; MEDLINE; MENTAL DISEASE; NEUTROPENIA; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA;

EID: 33645551868     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(06)73154-2     Document Type: Article

References (176)

1. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004;40:319-26.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 ;358:958-65.
4. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001;8:48-62.
5. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
6. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-55.
7. Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40:1450-8.
8. Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis 2002;185(Suppl 2):128-37.
9. Intron A (interferon alfa-2b, recombinant for injection) prescribing information. Kenilworth, NJ : Schering Corporation, February, 2001.
10. McHutchison J, Blatt L, Sedghi-Vaziri A, Russell J, Schmid P, Conrad A. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
11. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
12. Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473-7.
13. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004;11:243-50.
14. Balan V, Schwartz D, Wu GY, Muir AJ, Ghalib R, Jackson J, et al. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol 2005;100:299-307.
15. Gaeta GB, Precone DF, Felaco FM, Bruno R, Spadaro A, Stornaiuolo G, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1633-9.
16. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
17. Barbaro G, Di Lorenzo G, Belloni G, Ferrari L, Paiano A, Del Poggio P, et al. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. Am J Med 1999;107:112-8.
18. Gane E. Treatment of recurrent hepatitis C. Liver Transpl. 2002;8(Suppl 1):S28-37.
19. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002;123:141-51.
20. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004
21. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
22. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
23. Kurschel E, Metz-Kurschel U, Niederle N, Aulbert E. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2b in patients with myeloproliferative syndromes. Ren Fail 1991;13:87-93.
24. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995;13:2401-7.
25. Tarumi T, Sawada K, Sato N, Kobayashi S, Takano H, Yasukouchi T, et al. Interferon-alpha-induced apoptosis in human erythroid progenitors. Exp Hematol 1995;23:1310-8.
26. Canonico PG, Kastello MD, Cosgriff TM, Donovan JC, Ross PE, Spears CT, et al. Hematological and bone marrow effects of ribavirin in rhesus monkeys. Toxicol Appl Pharmacol 1984;74:163-72.
27. Van Vherbergh H, Delanghe JR, De Vos M, Leroux-Roel G; BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001;34:911-6.
28. Loustaud-Ratti V, Alain S, Lemonnier L, Marquet P, Denis F, Lunel F, et al. Ribavirin pharmacokinetic study will lead to individual dose adjustment in chronic hepatitis C patients. (abstract). Hepatology 2004(Suppl 1);40:405.
29. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000;22:555-65.
30. Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004;11:84-7.
31. Rebetron (combination therapy containing Rebetol [ribavirin, USP] capsules and Intron A [interferon alfa-2b, recombinant injection]) prescribing information, Kenilwoth, NJ: Schering, January 2001.
32. Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1623-32.
33. Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis 2003;37(Suppl 4):315-22.
34. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003;47:124-9.
35. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:378-81.
36. Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004;164:262-76.
37. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985;82:7580-4.
38. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003;228:1-14.
39. Talal AH, Weisz K, Hau T, Kreiswirth S, Dieterich DT. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. Am J Gastroenterol 2001;96:2802-4.
40. Gergely AE, Lafarge P, Fouchard-Hubert I, Lunel-Fabiani F. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology 2002;35:1281-2.
41. Lunel-Fabiani F, Fouchard-Hubert I, Gergely AE. Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C] Pathol Biol (Paris) 2003;51:520-4.
42. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9.
43. Di Fazio I, Motta M, Musumeci S, Neri S, Pistone G, Malaguarnera M. Efficacy of human recombinant erythropoietin plus IFN-alpha in patients affected by chronic hepatitis C. J Interferon Cytokine Res 2004;24:594-9.
44. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
45. Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40:1450-8.
46. Younossi ZM, Ong JP, Collantes R, Assmann JS, Sjogren R, Sjogren M, et al. Darbepoietin alfa for ribavirin-induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirn : a preliminary analysis (abstract). Gastroenterology 2004;126(supp 2):83.
47. th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC:American Society for Microbiology, 1999:415.
48. Carrat F, Bam-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-48.
49. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-36.
50. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-9.
51. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-50.
52. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
53. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-95.
54. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002;9:295-303.
55. Mangoni ED, Marrone A, Saviano D, Del Vecchio C, Utili R, Ruggiero G. Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia. Antivir Ther 2003;8:57-63.
56. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
57. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
58. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.
59. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 2001;8:287-92.
60. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005;41:275-9.
61. Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002;24:701-8.
62. Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drugs 2002;3:680-3.
63. Sagir A, Wettstein M, Heintges T, Haussinger D. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. Dig Dis Sci 2002;47:562-3.
64. Russo F, Bacosi M, Miglioresi L, Ricci GL. Leucopenia is a side effect of combination therapy for hepatitis C infection. Am J Gastroenterol 2000;95:1100-1.
65. Ernstoff MS, Kirkwood JM. Changes in the bone marrow of cancer patients treated with recombinant Interferon alpha-2. Am J Med 1984;76:593-6.
66. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 Suppl 1):237-44.
67. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-9.
68. Renou C, Harafa A, Bouabdallah R, Demattei C, Cummins C, Rifflet H, et al. Severe neutropenia and post-hepatitis C cirrhosis treatment: is interferon dose adaptation at once necessary? Am J Gastroenterol 2002;97:1260-3.
69. Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 1999;133:15-22.
70. Nemunaitis J. A comparative review of colony-stimulating factors. Drugs 1997;54:709-29.
71. Crowe SM, Lopez A. GM-CSF and its effects on replication of HIV-1 in cells of macrophage lineage. J Leukoc Biol 1997;62:41-8.
72. Martin J, Quiroga JA, Bosch O, Carreno V. Changes in cytokine production during therapy with granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B. Hepatology 1994;20:1156-61.
73. Martin J, Bosch O, Moraleda G, Bartolome J, Quiroga JA, Carreno V. Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B. Hepatology 1993;18:775-80.
74. Martin J, Quiroga JA, Navas S, Pardo M, Carreno V. Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells. Cytokine 1999;11:267-73.
75. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997;25:449-58.
76. Fukuda A, Kobayashi H, Teramura K, Yoshimoto S, Ohsawa N. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines Cell Mol Ther 2000;6:149-54.
77. Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995;42:907-12.
78. Higashi Y, Sakai K, Tada S, Miyase S, Nakamura T, Kamio T, et al. Case report: agranulocytosis induced by interferon-alpha therapy for chronic hepatitis C. J Gastroenterol Hepatol 1996;11:1012-5.
79. Carreno V, Parra A, Navas S, Quiroga JA. Granulocyte-macrophage colony-stimulating factor as adjuvant therapy for factor as adjuvant therapy for interferon alpha treatment of chronic hepatitis C. Cytokine 1996;8:318-22.
80. Carreno V, Martin J, Pardo M, Brotons A, Anchia P, Navas S, et al. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C. Cytokine 2000;12:165-70.
81. Martin J, Navas S, Quiroga JA, Carreno V. Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients. Cytokine 1996;8:313-7.
82. Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. J Hepatol 1998;28:382-9.
83. Gutierrez G, Pereda A. Granulocyte colony stimulating factor for the treatment of interferon-induced neutropenia in patients with chronic hepatitis B. J Pediatr Gastroenterol Nutr 2001;32:225.
84. Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001;7:181-90.
85. Winston DJ, Foster PF, Somberg KA, Busuttil RW, Levy MF, Sheiner PA, et al. Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. Transplantation 1999;68:1298-304.
86. Beckebaum S, Cicinnati VR, Zhang X, Malago M, Dirsch O, Erim Y, et al. Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study. Transplant Proc 2004;36:1489-91.
87. Neff GW, Montalbano M, O'Brien CB, Nishida S, Safdar K, Bejarano PA, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004;78:1303-7.
88. Martin TG, Schuman MA. Interferon-induced thrombocytopenia: is it time for thrombopoietin. Hepatology 1998;28:1430-2.
89. Peck-Radosavljevic M, Zacherl J, Meng YG, Pidlich J, Lipinski E, Langle F, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997;27:127-31.
90. Peck-Radosavljevic M, Wichlas M, Pidlich J, Sims P, Meng G, Zacherl J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998;28:1424-9
91. Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996;24:135-40.
92. Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol 2005;39(1 Suppl):9-13.
93. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 Suppl 1):237-44.
94. Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H. Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 1992;79:327-31.
95. Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999;104:1527-37.
96. Trepicchio WL, Wang L, Bozza M, Dorner AJ. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J Immunol 1997;159:5661-70.
97. Neumega (recombinant human IL-11 ;oprelvekin) [package insert]. Cambridge, MA: Genetics Institute, 2002.
98. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558-85.
99. Gordon MS, McCaskill-Stevens WJ, Battiato LA, Loewy J, Loesch D, Breeden E, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996;87:3615-24.
100. Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997;15:3368-77.
101. Artz AS, Ershler WB, Rustgi V. Interleukin-11 for thrombocytopenia associated with hepatitis C. J Clin Gastroenterol 2001;33:425-6.
102. Rustgi VK, Lee P, Finnegan S, Ershler W. Safety and efficacy of recombinant human interleukin-11 in combination with interferon/ribavirin therapy in hepatitis C patients with thrombocytopenia. Hepatology 2002;36:361A.
103. Ghalib R, Levine C, Hassan M, McClelland T, Goss J, Stribling R, et al. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology 2003;37:1165-71.
104. Trepicchio WL, Bozza M, Pedneault G, Dorner AJ. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996;157:3627-34.
105. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994;179:1529-37.
106. Lawitz EJ, Hepburn MJ, Casey TJ. A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. Am J Gastroenterol 2004;99:2359-64.
107. Cotreau MM, Stonis L, Strahs A, Schwertschlag US. A multiple-dose, safety, tolerability, pharmacokinetics and pharmacodynamic study of oral recombinant human interleukin-11 (oprelvekin). Biopharm Drug Dispos 2004;25:291-6.
108. Von Herbay A, de Groot H, Hegi U, Stremmel W, Strohmeyer G, Sies H. Low vitamin E content in plasma of patients with alcoholic liver disease, hemochromatosis and Wilson's disease. J Hepatol 1994;20:41-6.
109. Von Herbay A, Stahl W, Niederau C, von Laar J, Strohmeyer G, Sies H. Diminished plasma levels of vitamin E in patients with severe viral hepatitis. Free Radic Res 1996;25:461-6.
110. Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol 2002;97:2634-9.
111. Mahmood S, Yamada G, Niiyama G, Kawanaka M, Togawa K, Sho M, et al. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free Radic Res 2003;37:781-5.
112. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997;113:1069-73.
113. Ota Y, Sasagawa T, Suzuki K, Tomioka K, Nagai A, Niiyama G, et al. Vitamin E supplementation increases polyunsaturated fatty acids of RBC membrane in HCV-infected patients. Nutrition 2004;20:358-63.
114. Saeian K, Bajaj JS, Franco J, Knox JF, Daniel J, Peine C, et al. High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard alpha-interferon and ribavirin. Aliment Pharmacol Ther 2004;20:1189-93.
115. Morisco F, Vitaglione P, Carbone A, Stingo S, Scarpati S, Ascione A, et al. Tomato-based functional food as interferon adjuvant in HCV eradication therapy. J Clin Gastroenterol 2004;38(6 Suppl):118-20.
116. Greenberg ER. Vitamin E supplements: good in theory, but is the theory good? Ann Intern Med 2005;142:75-6.
117. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
118. Brass CA, Piken E. Do antioxidants ameliorate ribavirin related anemia in HCV patients. Gastroenterology 1999;116:L56.
119. Meister A. New developments in glutathione metabolism and their potential application in therapy. Hepatology 1984;4:739-42.
120. Ting CC, Hargrove ME, Liang SM, Liang CM, Sharrow SO. Dichotomy of glutathione regulation of the activation of resting and preactivated lymphocytes. Cell Immunol 1992;142:40-53.
121. Kalebic T, Kinter A, Poli G, Anderson ME, Meister A, Fauci AS. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteme. Proc Natl Acad Sci USA 1991;88:986-90.
122. Weiss L, Hildt E, Hofschneider PH. Anti-hepatitis B virus activity of N-acetyl-L-cysteine (NAC): new aspects of a well-established drug. Antiviral Res 1996;32:43-53.
123. Beloqui O, Prieto J, Suarez M, Gil B, Qian CH, Garcia N, et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res 1993;13:279-82.
124. Ideo G, Bellobuono A, Tempini S, Mondazzi L, Airoldi A, Benetti G, et al. Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Eur J Gastroenterol Hepatol 1999;11:1203-7.
125. Cimino L, Belisario MA, Intrieri M, D'Ascoli B, Sacchetti L, Salvatore F, et al. Effect of N-acetyl-cysteine on lymphomonocyte glutathione and response to interferon treatment in C-virus chronic hepatitis. Ital J Gastroenterol Hepatol 1998;30:189-93.
126. Look MP, Gerard A, Rao GS, Sudhop T, Fischer HP, Sauerbruch T, et al. Interferon/antioxidant combination therapy for chronic hepatitis C-a controlled pilot trial. Antiviral Res 1999;43:113-22.
127. Bernhard MC, Junker E, Hettinger A, Lauterburg BH. Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine. J Hepatol 1998;28:751-5.
128. Grant PR, Black A, Garcia N, Prieto J, Garson JA. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study. J Med Virol 2000;61:439-42.
129. Neri S, Ierna D, Antoci S, Campanile E, D'Amico RA, Noto R. Association of alpha-interferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva Med 2000;42:187-92.
130. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol 2001;35:134-46.
131. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36:525-31.
132. Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993;19:459-64.
133. Boucher E, Guyader D, Jacquelinet S, Andre P, Mendier MH, Turlin B, et al. Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients. Dig Liver Dis 2000;32:29-33.
134. Angelico M, Gandin C, Pescarmona E, Rapicetta M, Del Vecchio C, Bini A, et al. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995;90:263-9.
135. Chen W, Liu J, Gluud C. Bile acids for viral hepatitis. Cochrane Database Syst Rev 2003;2:CD003181.
136. Peterson TC. Inhibition of fibroproliferation by pentoxifylline. Activity of metabolite-1 and lack of role of adenosine receptors. Biochem Pharmacol 1996;52:597-602.
137. Peterson TC, Neumeister M. Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism. Immunopharmacology 1996;31:183-93.
138. Moser M, Zhang M, Gong Y, Johnson J, Kneteman N, Minuk GY. Effect of preoperative interventions on outcome following liver resection in a rat model of cirrhosis. J Hepatol 2000;32:287-92.
139. Chiao TB, Lee AJ. Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis. Ann Pharmacother 2005;39:516-22.
140. Kraus MR, Schafer A, Csef H, Scheurlen M, Faller H. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000;41:377-84.
141. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999;19(Suppl 1):67-75.
142. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987;147:1577-80.
143. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004;82:175-90.
144. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-11.
145. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
146. Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, et al. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J 2000;6:139-45.
147. Rifflet H, Vuillemin E, Oberti F, Duverger P, Laine P, Garre JB, et al. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha. Gastroenterol Clin Biol 1998; 22:353-7.
148. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-3.
149. Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RL. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 2000;7:211-7.
150. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003;25:34-8.
151. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999;340:1370.
152. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-7.
153. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-9.
154. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S, et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 1995;268:1763-6.
155. New AS, Gelernter J, Yovell Y, Trestman RL, Nielsen DA, Silverman J, et al. Tryptophan hydroxylase genotype is associated with impulsive-aggression measures: a preliminary study. Am J Med Genet 1998;81:13-7.
156. McAllister-Williams RH, Young AH, Menkes DB. Antidepressant response reversed by interferon. Br J Psychiatry 2000;176:93.
157. Sammut S, Bethus I, Goodall G, Muscat R. Antidepressant reversal of interferon-alpha-induced anhedonia. Physiol Behav 2002;75:765-72.
158. Schafer M, Schmidt F, Amann B, Schlosser S, Loeschke K, Grunze H. Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 2000;42(Suppl 1):43-5.
159. Goldman LS. Successful treatment of interferon alfa-induced mood disorder with nortriptyline. Psychosomatics 1994;35:412-3.
160. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002;63:194-8.
161. Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999;40:510-2.
162. Farah A. Interferon-induced depression treated with citalopram. J Clin Psychiatry 2002;63:166-7.
163. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertrahne treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000;173:359-61.
164. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993;88:760-1.
165. Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004;18:41-6.
166. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44:104-12.
167. Kraus MR, Schafer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005; 12:96-100.
168. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54:700-5.
169. Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 2004;365:87-91.
170. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ, et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005;19:23-7.
171. Castéra L, Constant A, Demotes-Mainard J, Couzigou P, Henry C. Prevalent manic symptoms in peginterferon-induced mood disorders in patients with chronic hepatitis C: therapeutic implications (abstract). Hepatology 2004(suppl 1);40:429.
172. Hauser P, Soler R, Reed S, Kane R, Gulati M, Khosla J, et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000;41:439-41.
173. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-6.
174. Castéra L, Constant A, Henry C, Couzigou P. Manifestations psychiatriques au cours du traitement de l'hépatite chronique C. Gastroenterol Clin Biol 2005;29:123-33.
175. Weinrieb RM, Auriacombe M, Lynch KG, Chang KM, Lewis JD. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry 2003;64:1502-10.
176. Zein NN, Arslan M, Dickson RC, Gross JB, Czaplewski LA, Petterson TM, et al. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients, with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22.